CN1923268A - Medicinal composition for treating rhinitis, its preparing method and quality controlling means - Google Patents
Medicinal composition for treating rhinitis, its preparing method and quality controlling means Download PDFInfo
- Publication number
- CN1923268A CN1923268A CN 200510200509 CN200510200509A CN1923268A CN 1923268 A CN1923268 A CN 1923268A CN 200510200509 CN200510200509 CN 200510200509 CN 200510200509 A CN200510200509 A CN 200510200509A CN 1923268 A CN1923268 A CN 1923268A
- Authority
- CN
- China
- Prior art keywords
- solution
- add
- water
- methanol
- weight portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal composition for treating rhinitis, which is prepared from Chinese medicinal herbs including dahurian angelica root, flower bud of lily magnolia, siberian cocklebur fruit, centipeda, scallion stalk, roor of sessile stemona, astragalus root, and schisandra fruit. The invention The invention also discloses the method for preparing the medicinal composition and its quality control method.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, especially a kind of Chinese medicine composition that is used for the treatment of rhinitis belongs to the field of Chinese medicines.The present invention has also related to this preparation of drug combination method and method of quality control simultaneously.
Background technology
Allergic rhinitis also claim allergic rhinitis, are equivalent to the allergic rhinitis of the traditional Chinese medical science, and exopathogenic factor sucks the nature anaphylactogen, endogenous cause of ill heritability allergic constitution, " interaction between two asthenia conditions is its shape of visitor ".Primary disease is global commonly encountered diseases, frequently-occurring disease, according to statistics, prevalence is 10% ~ 40%, China's prevalence is 37.74%, and annual number of the infected has more than 2,000 ten thousand approximately, causes on the physiology with psychological unhappy and painful to the patient, have a strong impact on operate as normal and interpersonal communication, and prolonged and repeated outbreak, can cause serious pathologic lesion, merge nasal polyp, persistence cough and bronchial asthma etc.Because primary disease and extraneous natural environment is closely related, the allergen variability is strong, is difficult to determine that very easily recurrence is difficult to thoroughly cure.In recent years, since the continuous deterioration of environment for human survival, the variation of intrinsic factor such as physical stress, and the sickness rate of allergic rhinitis has the trend that rises year by year.Although the medical science fast development, new drug continues to bring out, and the whole world especially sickness rate of industrialized country's allergic rhinitis still significantly rises.So far still there is not good Therapeutic Method.The etiology and pathogenesis of relevant primary disease, the problems such as development of associated treatment medicine are subjected to extensive attention, and its research is deepened continuously.
Western medicine present situation: at present, the Therapeutic Principle of primary disease is remained: 1. avoid sucking the anaphylactogen that can excite; 2. Drug therapy; 3. antigenic desensitization treatment.The first, thus avoid antigenic suction minimizing or disease does not take place, ideal undoubtedly, but be difficult to realize.The second, using suitable Drug therapy still is topmost treatment measure.The 3rd, though desensitization therapy has plurality of advantages than the antihistamine treatment that can only improve symptom, need for several years running, and only can reach the purpose of mitigation symptoms, reports such as the mental excitation of generation and acute bone necrosis are arranged again.At present, be mainly used in the Western medicine for the treatment of primary disease five classes are arranged: antihistaminic, decongestant drug, anticholinergic agent, mast cell stabilizers and corticosteroid medication.
Antihistaminic still is proposed as choice drug.Though its second filial generation antihistaminic has reduced the anticholinergic side effects of the first generation: drowsiness, xerostomia, blurred vision, urine pool stream etc., serious liver function injury is arranged or bring out potential cardiovascular disease, the patient should use cautiously.The antihistamine drug of improving symptom is different with being only limited to, and immunization therapy is to be based on changing this patient's immunoreation and to reach the clinical treatment purpose, but the problem that immunization therapy exists is very important, aspect safety, the possibility of bringing out severe allergic reaction is arranged.In recent years the someone proposes, and perhaps Allergic Rhinitis is depended on Drug therapy unduly is the key factor that causes present asthma prevalence to increase year by year.Excessively use immunotherapeutic agents such as hormone, antihistamine can suppress immune system, make the touching difficulty of this type of disease more.So that many anaphylactic disease patients all show the unusual and immune defense system of mucosa permeability a little less than.
The traditional Chinese medical herbal treatment present situation: the traditional Chinese medical science is to existing more than 2000 year history of development of primary disease treatment prescription.From the Huangdi's Internal Classics to the Qing Dynasty 1773 " miscellaneous diseases source and course rhinoceros candle ", many medical science ancient books and records have carried out comprehensive elaboration to primary disease.Documents and materials analyses such as the contained summary report of the domestic and international periodical that comes according to recent two decades, clinical treatise, experimentation, pathogen and pathology of tcm shortage new statement, though Therapeutic Principle's method, approach are many, not outer dispelling wind and ventilating the lung, promoting diuresis to eliminate damp pathogen, blood yiqi are normal.In recent years, domestic in medical circles generally accept the irritated theory of allergic rhinitis doctor trained in Western medicine, serve as the research point of penetration to regulate immune state, to set upright desensitization, on the mirror that lime light is placed on nasal mucosa changes down.Treat but Therapeutic Principle's method still is in based on the endo-medicine of dispelling wind and ventilating the lung, promoting diuresis to eliminate damp pathogen, invigorating the spleen and replenishing QI, its etiology and pathogenesis lacks new statement.
As topic project verification research, be commonly encountered diseases, frequently-occurring disease based on allergic rhinitis, and quick-acting on the market, efficient, safety, during late result is satisfied, toxic and side effects is little, the insufficient treatment present situation of Western medicine kind.Our research purpose will can reduce recurrence again for extensive patients provides rapid-action a, short treating period exactly, and late result is good, the Chinese medicine new varieties of no obvious toxicity.
Summary of the invention
The inventor has reached its goal of the invention by following technical solution through research for many years.
At first the inventor has invented a kind of pharmaceutical composition, and this pharmaceutical composition is to be made by the crude drug of following part by weight:
The Radix Angelicae Dahuricae 190～230 weight portion Flos Magnoliaes 120～160 weight portion Fructus Xanthii 120～160 weight portions
Very light blue 120～160 weight portion Radixs Stemonae of Herba Centipedae 120～160 weight portions 120～160 weight portions
The Radix Astragali 120～160 weight portion Fructus Schisandrae Chinensis 55～85 weight portions.
Crude drug proportioning after preferred is:
The Radix Angelicae Dahuricae 200～220 weight portion Flos Magnoliaes 130～150 weight portion Fructus Xanthii 130～150 weight portions
Very light blue 130～150 weight portion Radixs Stemonae of Herba Centipedae 130～150 weight portions 130～150 weight portions
The Radix Astragali 130～150 weight portion Fructus Schisandrae Chinensis 65～75 weight portions.
Obtain optimal proportion after further preferred: the Radix Angelicae Dahuricae 211 weight portions, Flos Magnoliae 141 weight portions, Fructus Xanthii 141 weight portions, Herba Centipedae 141 weight portions, very light blue 141 weight portions, the Radix Stemonae 141 weight portions, the Radix Astragali 141 weight portions, Fructus Schisandrae Chinensis 70 weight portions.
With above crude drug, common process through pharmaceutics, as extract, concentrate, steps such as drying, preparations shaping, can make attainable multiple dosage form on clinical or the pharmaceutics, comprise tablet, capsule, granule, soft capsule, oral liquid etc.
Subsequently, the inventor studies concrete preparation technology again, and the PRELIMINARY RESULTS that obtains is:
1) Radix Angelicae Dahuricae, the Radix Stemonae, Fructus Schisandrae Chinensis add 70%～90% alcohol reflux, and extracting solution reclaims ethanol, and is concentrated into into clear paste;
2) Flos Magnoliae extracts volatile oil with steam distillation, and the aqueous solution of carrying behind the oil is continued to employ; Volatile oil betacyclodextrin inclusion;
3) decoct with water after Flos Magnoliae medicinal residues and Fructus Xanthii, the Radix Astragali, Herba Centipedae, the very light blue mixing, decoction liquor filters, filtrate for later use;
4) with 2) in carry aqueous solution and 3 behind the oil) in filtrate merge, be condensed into clear paste, add ethanol and make and contain alcohol amount and reach 60%～80%, placement is spent the night, filter, filtrate recycling ethanol also concentrates clear paste, with 1) middle alcohol extraction clear paste merging, continue to be condensed into thick paste, drying under reduced pressure, be ground into fine powder, again with 2) in inclusion complex mixes, must medicated powder;
5) the conventional adjuvant of medicated powder and pharmaceutics is mixed mutually, make required dosage form.
The inventor studies multiple dosage form, thinks that finally capsule is excellent dosage form, and its preparation process is as follows:
1) Radix Angelicae Dahuricae, the Radix Stemonae, Fructus Schisandrae Chinensis add 5 times of amount alcohol reflux of 80% 3 times, and each 2 hours, filter, merge alcohol extract, reclaim ethanol, relative density is the clear paste of 1.05-1.10 when being concentrated into 50 ℃;
2) Flos Magnoliae adds 8 times of amounts of water, and steam distillation 6 hours extracts volatile oil, and the aqueous solution of carrying behind the oil is continued to employ; Volatile oil betacyclodextrin inclusion;
3) add 12 times of amounts of water after Flos Magnoliae medicinal residues and Fructus Xanthii, the Radix Astragali, Herba Centipedae, the very light blue mixing, decoct 3 times, each 1 hour, filter filtrate for later use;
4) with 2) in carry aqueous solution and 3 behind the oil) in filtrate merge, relative density is the clear paste of 1.05-1.10 when being concentrated into 50 ℃, adds ethanol and makes and contain alcohol amount and reach 70%, and placement is spent the night, filter, filtrate recycling ethanol and to be concentrated into 50 ℃ of relative densities be 1.10-1.15 is with 1) in the alcohol extraction clear paste merge, relative density is the thick paste of 1.25-1.30 when continuing to be concentrated into 50 ℃, drying under reduced pressure, be ground into fine powder, again with 2) in inclusion complex mixes, must medicated powder;
5) medicated powder is added lactose on a small quantity to regulate medicated powder to suitable degree of adhesion, dry-pressing is granulated, and dresses up capsule.
It should be noted that in above preparation process, the preparation condition of betacyclodextrin inclusion complex is: the weight ratio of volatile oil-betacyclodextrin-water is 1: 8: 60, stir 1 hour inclusion under 80 ℃ of conditions, cold preservation is spent the night again, sucking filtration, inclusion complex be lower than under 40 ℃ the condition dry, promptly.
In the process of this preparation of pharmaceutical compositions method of research, to use the method for quality control of some of them crude drug all the time, the inventor has carried out the raising of system through research with these quality methods, makes it can effectively control the quality of final products.The method of quality control of this pharmaceutical composition comprises qualitative identification and assay two parts, below narration respectively.
Qualitative identification comprises following one or more:
1) get preparation 3～5g of the present invention and put in the tool plug conical flask, the 50ml that adds diethyl ether, supersound process 20 minutes filters, and filtrate is put evaporate to dryness in the water-bath, and residue adds methanol 1ml dissolving, as need testing solution; Other gets imperatorin, isoimperatorin reference substance, adds methanol and makes the solution that every ml contains 1mg, in contrast product solution; According to the thin layer chromatography test, draw above-mentioned need testing solution 10ul, reference substance solution 5ml, put respectively on same silica gel g thin-layer plate, be developing solvent with petroleum ether-ether of 3: 2, launch, take out, dry, put under the 365nm ultra-violet lamp and inspect; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
2) getting preparation 3～5g of the present invention puts in the round-bottomed flask, add methanol 50ml, reflux 1 hour filters, the methanol solution evaporate to dryness, residue adds water 30ml dissolving, uses water saturation n-butanol extraction 2 times, each 20ml, merge n-butyl alcohol liquid, extract 3 times with ammonia solution, each 20ml discards ammonia solution, n-butyl alcohol liquid is put evaporate to dryness in the water-bath, residue adds water 10ml dissolving, by macroporous resin column, respectively with water 50ml, 40% ethanol 50ml, 70% ethanol 50ml eluting, collect 70% ethanol elution, evaporate to dryness, residue add methanol 1ml dissolving, as need testing solution; Other gets the astragaloside reference substance, adds methanol and makes the solution that every ml contains 1mg, in contrast product solution; Test according to thin layer chromatography, draw above-mentioned need testing solution 5ml, reference substance solution 2 ~ 3ml, put respectively on same silica gel g thin-layer plate, lower floor's solution with 13: 7: 2 chloroform-methanol-water is developing solvent, launch, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and 100 ℃ to be heated to the speckle colour developing clear; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, the speckle of apparent same color under the daylight; Under the 365nm ultra-violet lamp, show the fluorescence speckle of same color;
3) get preparation 3～5g of the present invention and add 10% sodium hydroxide solution 100ml, heating in water bath refluxed 1 hour, put cold, solution is inclined to separatory funnel, use ethyl acetate extraction 2 times, each 50ml, merge ethyl acetate liquid, wash with water to neutrality, reclaim ethyl acetate and be concentrated into about 1ml, as need testing solution; Other gets Fructus Xanthii control medicinal material 6g, add 10% sodium hydroxide solution 100ml, heating in water bath refluxed 1 hour, put cold, centrifugal, get supernatant ethyl acetate extraction 2 times, each 50ml merges ethyl acetate liquid, washes with water to neutrality, reclaim ethyl acetate and be concentrated into about 1ml, make control medicinal material solution; According to the thin layer chromatography experiment, draw above-mentioned two kinds of each 5ml of solution, put respectively on same silica gel G plate, be developing solvent with toluene-ethyl acetate-glacial acetic acid of 16: 4: 1, launch, take out, dry, put in the iodine vapor and smoked 5 minutes; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color;
4) get preparation 3～5g of the present invention, add water 30ml dissolving, add ammonia solution 15ml, change in the separatory funnel, add chloroform 50ml extraction, shake well divides and gets chloroform solution, and evaporate to dryness, residue add methanol 1ml dissolving, as need testing solution; Other gets Radix Stemonae control medicinal material 1.5g, adds methanol 10ml ultrasonic 10 minutes, filters, and the filtrate evaporate to dryness adds water 10ml dissolving, add ammonia solution 15ml, change in the separatory funnel, add chloroform 50ml extraction, shake well, divide and get chloroform solution, evaporate to dryness, residue add methanol 1ml dissolving, make control medicinal material solution; Test according to thin layer chromatography, draw above-mentioned two kinds of each 10ul of solution, put respectively on the silica gel g thin-layer plate that same usefulness 1% sodium hydroxide solution is modulated into, with 40: 40: 15: lower floor's solution that chloroform-ethyl acetate of 15-methanol-water is placed below 10 ℃ was developing solvent, launch, take out, dry, spray is with rare bismuth potassium iodide test solution and 5% sodium nitrite alcoholic solution; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color;
5) get preparation 3～5g of the present invention, add ethyl acetate 30ml, supersound process 20 minutes filters, and filtrate evaporate to dryness, residue add methanol 1ml dissolving, as need testing solution; Other gets Fructus Schisandrae Chinensis control medicinal material 1g, shines medical material solution in pairs with legal system; Get the schisandrin reference substance again, add methanol and make the solution that every ml contains 1mg, in contrast product solution; According to the thin layer chromatography test, draw above-mentioned three kinds of each 5ml of solution, put in same silica gel G F respectively
254On the lamellae, be developing solvent, launch, take out, dry, put under the 254nm ultra-violet lamp and inspect with the upper solution of petroleum ether-Ethyl formates of 15: 5: 1-formic acid; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescent quenching speckle of same color; With the corresponding position of reference substance chromatograph on, show the fluorescent quenching speckle of same color.
Assay then is such:
Chromatographic condition and system suitability test octadecyl silane are filler; 50: 50 acetonitrile-water is a mobile phase; The detection wavelength is 250nm; 23 ℃ of column temperatures; Flow velocity 1.2ml/min; Number of theoretical plate calculates by imperatorin, should be not less than 3000;
It is an amount of that the imperatorin reference substance is got in the preparation of reference substance solution, and accurate the title decides, and adds methanol and makes the solution that every ml contains 12mg, as need testing solution;
Preparation 2～3g of the present invention is got in the preparation of need testing solution, and accurate the title decides, and puts in the 50ml volumetric flask, add chloroform 30ml, supersound process 30 minutes is put cold, add chloroform to scale, shake up, filter, precision is measured subsequent filtrate 10ml, puts evaporate to dryness in the evaporating dish, and residue adds dissolve with methanol, and move in the 5ml volumetric flask, add methanol and be diluted to scale, methanol solution filters with microporous filter membrane, as need testing solution;
Accurate respectively reference substance solution 10ml, the need testing solution 10ml of drawing of algoscopy injects chromatograph of liquid, measures, promptly;
Contain the Radix Angelicae Dahuricae in imperatorin in the medicated powder of preparation of the present invention, must not be less than 1.33mg in every gram.
So far, the inventor has finished its summary of the invention substantially, reaches its goal of the invention.This drug regimen has expelling wind and cold, and lung qi dispersing is sensible, and QI invigorating is held back the effect in Tianjin, is used for the treatment of allergic rhinitis, similar traditional Chinese medical science allergic rhinitis disease person.For proving its drug effect, the inventor has carried out zoopery.
1. test material
1.1 medicine
The capsule for treating rhinitis extract: by best techniques method preparation of the present invention, every milliliter contains crude drug 2.72 grams, lot number is provided by Huaxia Yisheng Innovation Science ﹠ Tech. Co., Ltd., Beijing: 20021030, become respective concentration with before adding an amount of distilled water diluting.Aspirin tablet: the 0.5g/ sheet, produce lot number: 20010305 by Jiamusi second pharmaceutical factory.The BIYANKANG sheet: Foshan Dezhong Pharmaceutical Co., Ltd. produces, and every contains 1 milligram of chlorphenamine, lot number: 0207360.Egg protein lyophilized powder: the packing of Sigma company, article No.: A5253.Freund adjuvant: liquid paraffin adds lanoline (2: 1) and is total to heat to 70 ℃, shakes up, and autoclaving, standby.
1.2 animal
SD kind rat: male and female half and half, body weight 150-200 gram, the SPF level, available from dimension tonneau China laboratory animal company limited, the quality certification number: SCXK (capital) 2002-0003.Kunming mouse: female, male, body weight 18-20g, all available from Institute of Experimental Animals, Chinese Academy of Medical Sciences breeding factory, the animal quality certification number: SCXK 11-00-0006.
1.3 instrument
OLYMPUS AU 640 biochemical measurement instrument, Japan makes; Hot plate dolorimeter GJ-8420 type, Chinese Zhejiang produces.
2. test method and result
2.1 influence to the allergic rhinitis model
2.1.1 egg protein is caused the influence of rat allergic rhinitis model
After getting the rat adaptability and raising a week, back intradermal injection egg protein freund adjuvant Emulsion (freund adjuvant behind egg protein 10mg/ml and the autoclaving was with 1: the 1 fully emulsified Emulsion of making) 1ml/ only carries out active sensitization.Be divided into 6 groups after the sensitization at random, i.e. the quick large, medium and small dosage group of normal control group (back injecting normal saline), model control group, positive drug control group and Xin Zhi nose, 15 every group, per 5 one cages are raised.Each organize rat respectively at sensitization after the 5th day, according to the continuous gastric infusion of following table dosage 6 days, the administration volume was 0.5ml/100g.After the sensitization the 11st day, rat back intradermal injection 1% egg protein physiological salt liquid 0.1ml/ only, carry out the instantaneity intradermal test, select the rubescent scope in skin mound all to surpass the animal (point out animal all sensitization) of 10cm, 10 every group, male and female half and half, with 1% egg protein physiological salt liquid 0.1ml/ only, splash into (attack) animal bilateral nasal cavity, femoral artery is got blood behind the 0.5h, centrifugal, get the determination of serum amynologic index; Get one of whole blood, do blood smear, treat the specimen drying after, drip methanol and fix 2 minutes, Wright's stain dyeing 2 minutes, distilled water flushing is cleaned dye liquor, uprightly dries, oily mirror is counting oxyphil cell's quantity down; Nasal mucosa (in every) exfoliative cyte smear, Yihong dyeing, counting mast cell degranulation number; Divest upper jaw osseous part skin and will dissociate out in the upper jaw bone,, expose nasal septum and bilateral nasal cavity, earlier the preceding stage casing of nasal septum is cut off, be fixed in the 10% neutral formalin liquid along the nose midline incision.Flowing water flushing back dehydration, paraffin embedding, HE dyeing, om observation, the histopathologic examination of doing nasal mucosa.
2.1.1.1 the observed result of mode of appearance
The performance of allergic rhinitises such as the model group animal all has restlessness, the nose of scratching, sneeze; The normal control treated animal is not seen above-mentioned reaction; The above-mentioned reaction of each treated animal of administration all has to some extent and alleviates.
2.1.1.2 the testing result of seroimmunity index
Seroimmunity index IgA, IgG of model group animal and IgM value all obviously raise than normal matched group, the detected value of positive drug and the quick big or middle dosage treated animal of hot root of Dahurian angelica nose all has obvious reduction than the model group animal, and small dose group animal and model group be there was no significant difference (seeing Table 1) relatively.
2.1.1.3 the testing result of blood smear
Observed result under the oil mirror shows that the lymphocyte structure of normal control treated animal is normal; As seen the model group animal has the oxyphil cell to soak into, and neutral leaflet nuclear is more, and platelet is arranged, and oxyphil cell's quantity and normal control group comparing difference are remarkable; Positive drug and three dosed administration treated animals all have a spot of lymphocyte and neutral leaflet nuclear, and oxyphil cell's quantity all has different the minimizing, and big or middle dosage treated animal oxyphil cell's quantity and model control group comparing difference be (seeing Table 2) significantly.
2.1.1.4 the testing result of nasal mucosa exfoliative cyte smear
Add up according to the grade scale under the table 3, normal control treated animal nasal mucosa mastocyte does not see that the granule of taking off is arranged, and does not see inflammatory cell infiltration; The most of mast cell degranulation of model control group animal nasal mucosa, cell obviously increases, and a large amount of inflammatory cell infiltrations is arranged, and based on leukocyte, and more neutrophilia leaflet nuclear is arranged; The mast cell degranulation phenomenon of administration various dose group and positive drug treated animal nasal mucosa has in various degree and to reduce, and the mast cell degranulation number obviously reduces, and inflammatory cell infiltration has in various degree and alleviates (seeing Table 3,4).
2.1.1.5 the inspection of nasal mucosa histopathology
The nasal septum mucosa columnar epithelium of normal control treated animal is not seen and is thickened, and does not see inflammatory cell infiltration, and a matter is not seen squamous metaplasia, and organizational structure is normal; The performance of allergic rhinitises such as the model group animal all has restlessness, the nose of scratching, sneeze.Nasal septum is sticking to be touched epithelial cell and obviously thickens, cytosis, and a matter has squamaization, and a large amount of lymphocytes, mastocyte and oxyphil cell are arranged, and matter swelling between nasal mucosa is organized more loose.The nasal septum mucosa columnar epithelium of administration three dosage groups and positive drug group rat thickens, squamaization, inflammatory cell infiltration, and pathological changes such as a matter swelling all have to some extent and alleviate (seeing Table 5).
Table 1, egg protein is caused influence (X ± S that the allergic rhinitis rat immunity is learned index; N=10)
| Group | Dosage (g/kg) | IgA (g/L) | IgG (g/L) | IgM (g/L) |
| Dosage low dose in the normal control model contrast BIYANKANG sheet heavy dose | 4 4.6 2.3 1.15 | 0.11±0.02 0.25±0.11 # 0.16±0.03* 0.15±0.04* 0.10±0.05** 0.24±0.14 | 0.07±0.04 0.21±0.14 # 0.12±0.05 0.10±0.09* 0.10±0.05* 0.29±0.26 | 0.22±0.02 0.47±0.21 ## 0.29±0.09* 0.24±0.10** 0.27±0.10* 0.41±0.27 |
Annotate: T check between group: compare with the blank group:
#P＜0.05;
Compare with model group: * P＜0.05; * P＜0.01.
Table 2, to the influence (X ± S of oxyphil cell's quantity; N=10)
| Group | Dosage (g/kg) | Oxyphil cell's quantity (individual) |
| Dosage low dose in the normal control model contrast BIYANKANG sheet heavy dose | --4 4.6 2.3 1.15 | 0.7±0.6 2.0±1.1 # 0.8±0.6* 0.9±0.7* 1.0±0.6* 1.3±0.6* |
Annotate: T check between group: compare with the blank group:
#P＜0.05; Compare with model group: * P＜0.05.
Table 3, to the influence (X ± S of nasal mucosa mast cell degranulation number; N=10)
| Group | Dosage (g/Kg) | Mast cell degranulation number (individual) |
| Dosage low dose in the blank model contrast BIYANKANG sheet heavy dose | 4 4.6 2.3 1.15 | 0.0±0.00 6.7±1.34 ### 1.4±1.35*** 1.2±0.92*** 1.8±1.32*** 2.0±1.15** |
Annotate: T check between group: compare with the blank group:
###P＜0.001;
Compare with model group: * * P＜0.01; * * P＜0.001.
The influence (n=10) of table 4 pair nasal mucosa exfoliative cyte number
| Group | Dosage (g/Kg) | The mastocyte lesion degree | ||
| ++ | + | - | ||
| The low dose of * of dosage * among the heavy dose of * of blank model contrast * * BIYANKANG sheet * | --4 4.6 2.3 1.15 | 0 6 1 1 1 2 | 0 4 8 8 9 8 | 10 0 1 1 0 0 |
Annotate: rank test: compare with the blank group: ##P＜0.01; Compare with model group: *＜0.05.
Grade scale :-: normal mastocyte, do not have and take off granule.
+: mast cell degranulation is more rare, and a small amount of neutrophilic infiltration is arranged in the smear.
++: mast cell degranulation is more, neutrophilic leukocyte showed increased in the smear.
The influence (n=10) of table 5 pair nasal mucosa histopathology
| Group | Dosage (g/Kg) | Mucomembranous epithelial cell | Between matter | ||||||
| +++ | ++ | + | - | +++ | ++ | + | - | ||
| The contrast of blank model #The low dose of * of dosage * * among the heavy dose of * * of BIYANKANG sheet * * | --4 4.6 2.3 1.15 | 0 2 0 0 0 0 | 0 6 1 1 3 4 | 0 2 9 9 7 6 | 10 0 0 0 0 0 | 0 3 0 0 0 0 | 0 3 0 0 0 0 | 0 4 2 2 3 4 | 10 0 8 8 7 6 |
Annotate: order is closed check: compare with the blank group:
#P＜0.05;
Compare with model group: * P＜0.05; * P＜0.01.
Grade scale :-: normal configuration, nasal septum columnar epithelium do not have and thicken, a matter no cell infiltration of loosening.
+: the nasal septum columnar epithelium slightly thickens, and a matter is loosened a small amount of cell infiltration.
++: the nasal septum columnar epithelium thickens, and a matter is loose cell infiltration, and a spot of oxyphil cell and mastocyte are arranged.
+++: nasal septum columnar epithelium thickens more obvious, and a matter is loose more cell infiltration, and a large amount of oxyphil cells and mastocyte are arranged.
2.2 influence to scorching model of a syndrome
2.2.1 to the bullate influence of rat granuloma
Get 50 of the male rats of body weight 150-160 gram, under ether light anaesthesia condition, make abdominal incision, it is subcutaneous that the cotton balls of constant weight (30mg), sterilization has been implanted rat both sides groin, postoperative is divided into 5 groups at random, every group 10, operation this product on the same day with 4.6,2.3,1.15/Kg dosage begins gastric infusion, administration volume 0.5ml/100g, successive administration 7 days is with the positive contrast medicine of aspirin.Put to death animal on the 8th day, and peeled off and take out granulation tissue, weigh after 1 hour, deduct the raw cotton ball weight, be the granuloma net weight in 60-90 ℃ of baking oven inner drying.Relatively weight between the granuloma group is calculated suppression ratio.
The result shows that it is swollen that the quick capsule three dosage groups of hot root of Dahurian angelica nose all can suppress rat granuloma to some extent, compares with model group
Significant difference (seeing Table 6).
Table 6, to the bullate influence (X ± S of rat granuloma; N=10)
| Group | Dosage (g/Kg) | Granuloma dry weight (mg) | Suppression ratio (%) |
| Dosage low dose in the model aspirin heavy dose | 0.1 4.6 2.3 1.15 | 123.75±17.65 74.90±13.46*** 63.35±12.26*** 75.20±14.43*** 85.42±20.19** | 65.2 95.3 64.6 44.9 |
Annotate: T check between group: compare with model control group: * * P＜0.01; * * P＜0.001.
2.2.2 xylol causes the influence of mice ear
Getting body weight is 25-30 gram male mice, be divided into 5 groups at random, every group 10, with this product 5,2.5,1.25g/Kg gastric infusion is 3 days continuously, the dosage of positive drug aspirin is 0.1g/Kg, after the last administration dimethylbenzene 0.1ml is dripped in the two sides, front and back of mice left side ear with sample injector, auris dextra is put to death mice for contrast after 0.5 hour, cut two ears along the auricle baseline, card punch with the 8mm diameter is laid round auricle at same position respectively, organize balance to weigh, deduct the auris dextra sheet with the left ear of every Mus and heavily be the swelling degree, calculate average and the standard deviation of respectively organizing the swelling degree, calculate its suppression ratio, the comparable group differences.
The result shows that this product 5,2.5,1.25g/Kg dosage all can suppress the ear swelling of mice caused by dimethylbenzene xylene, and prompting this product has inhibitory action (seeing Table 7) definitely to the non-specific acute inflammation model of animal.
Table 7, to the influence (X ± S of mice ear; N=10)
| Group | Dosage (g/Kg) | Swelling degree (mg) | Suppression ratio (%) |
| Dosage low dose in the model aspirin heavy dose | 0.1 5.0 2.5 1.25 | 24.7±2.6 15.7±4.9** 15.8±2.9** 17.9±4.4* 20.4±3.0* | 57.3 52.5 27.5 21.1 |
Annotate: T check between group: compare with model control group: * P＜0.05; * P＜0.01.
The specific embodiment
Following inventor further sets forth technical scheme of the present invention by embodiment, but invention which is intended to be protected and only limit to the described dosage form of embodiment.
Embodiment 1:
Crude drug: Radix Angelicae Dahuricae 19kg, Flos Magnoliae 12kg, Fructus Xanthii 12kg, Herba Centipedae 12kg, very light blue 12kg, Radix Stemonae 12kg, Radix Astragali 12kg, Fructus Schisandrae Chinensis 5.5kg.
Preparation method: 1) Radix Angelicae Dahuricae, the Radix Stemonae, Fructus Schisandrae Chinensis add 8 times of amount alcohol reflux of 70% 2 times, and each 2 hours, extracting solution reclaimed ethanol, and are concentrated into into the clear paste of 1.05～1.10 (50 ℃);
2) Flos Magnoliae steam distillation 10 hours extracts volatile oil, and the aqueous solution of carrying behind the oil is continued to employ; Volatile oil betacyclodextrin inclusion;
3) add 10 times of water gagings after Flos Magnoliae medicinal residues and Fructus Xanthii, the Radix Astragali, Herba Centipedae, the very light blue mixing and decoct 2 times, each 1.5 hours, decoction liquor filtered, filtrate for later use;
4) with 2) in carry aqueous solution and 3 behind the oil) in filtrate merge, be condensed into 1.05～1.10 (50 ℃) clear paste, add ethanol and make and contain alcohol amount and reach 60%, placement is spent the night, filter, filtrate recycling ethanol also is condensed into clear paste, merges with alcohol extraction clear paste in the step 1), continues to be condensed into the thick paste of 1.25～1.35 (50 ℃), drying under reduced pressure, be ground into fine powder, again with 2) in inclusion complex mixes, must medicated powder;
5) add the 15kg dextrin in medicated powder, mixing is made granule.
Instructions of taking: three times on the one, each 4～5 grams are taken after mixing it with water.
Embodiment 2:
Crude drug: Radix Angelicae Dahuricae 23kg, Flos Magnoliae 16kg, Fructus Xanthii 16kg, Herba Centipedae 16kg, very light blue 16kg, Radix Stemonae 16kg, Radix Astragali 16kg, Fructus Schisandrae Chinensis 8.5kg
Preparation method: 1) Radix Angelicae Dahuricae, the Radix Stemonae, Fructus Schisandrae Chinensis add 90% alcohol reflux 3 times, and each 3 hours, extracting solution reclaimed ethanol, and are concentrated into into the clear paste of relative density 1.05～1.10 (50 ℃);
2) Flos Magnoliae adds 10 times of water gagings, and steam distillation 6 hours extracts volatile oil, and the aqueous solution of carrying behind the oil is continued to employ; Volatile oil betacyclodextrin inclusion;
3) add 12 times of water gagings of water after Flos Magnoliae medicinal residues and Fructus Xanthii, the Radix Astragali, Herba Centipedae, the very light blue mixing and decoct, decoction liquor filters, filtrate for later use;
4) with 2) in carry aqueous solution and 3 behind the oil) in filtrate merge, be condensed into the clear paste of relative density 1.05～1.10 (50 ℃), add ethanol and make and contain alcohol amount and reach 80%, placement is spent the night, filter, filtrate recycling ethanol also is condensed into the clear paste of relative density 1.05～1.10 (50 ℃), with 1) in the alcohol extraction clear paste merge, continue to be condensed into the thick paste of relative density 1.25～1.35 (50 ℃), drying under reduced pressure, be ground into fine powder, again with 2) in inclusion complex mixes, must medicated powder;
5) in medicated powder, add microcrystalline Cellulose 1kg and starch 8kg, mix homogeneously, compacting is in blocks, every heavy 0.4g.
Instructions of taking: three times on the one, each 4～5.
Embodiment 3:
Crude drug: Radix Angelicae Dahuricae 21.1kg, Flos Magnoliae 14.1kg, Fructus Xanthii 14.1kg, Herba Centipedae 14.1kg, very light blue 14.1kg, Radix Stemonae 14.1kg, Radix Astragali 14.1kg, Fructus Schisandrae Chinensis 7.0kg
Preparation method: 1) Radix Angelicae Dahuricae, the Radix Stemonae, Fructus Schisandrae Chinensis add 5 times of amount alcohol reflux of 80% 3 times, and each 2 hours, filter, merge alcohol extract, reclaim ethanol, being concentrated into relative density is the clear paste of 1.05-1.10 (50 ℃);
2) Flos Magnoliae adds 8 times of amounts of water, and steam distillation 6 hours extracts volatile oil, and the aqueous solution of carrying behind the oil is continued to employ; Volatile oil betacyclodextrin inclusion;
3) add 12 times of amounts of water after Flos Magnoliae medicinal residues and Fructus Xanthii, the Radix Astragali, Herba Centipedae, the very light blue mixing, decoct 3 times, each 1 hour, filter filtrate for later use;
4) with 2) in carry aqueous solution and 3 behind the oil) in filtrate merge, being concentrated into relative density is the clear paste of 1.05-1.10 (50 ℃), adds ethanol again and makes and contain the alcohol amount and reach 70%, placement is spent the night, filter, filtrate recycling ethanol, and to continue to be concentrated into relative density be 1.10-1.15 (50 ℃), with 1) middle alcohol extraction clear paste merging, continue to be concentrated into the thick paste that relative density is 1.25-1.30 (50 ℃), drying under reduced pressure is ground into fine powder, again with 2) in inclusion complex mixes, must medicated powder;
5) medicated powder is added lactose 45kg, dry-pressing is granulated, and dresses up capsule, every heavy 0.4g.
Instructions of taking: three times on the one, each 3～4.
Quality standard:
Differentiate: (1) is got this product 5g and is put in the tool plug conical flask, the 50ml that adds diethyl ether, and supersound process 20 minutes filters, and filtrate is put evaporate to dryness in the water-bath, and residue adds methanol 1ml dissolving, as need testing solution.Other gets imperatorin, isoimperatorin reference substance, adds methanol and makes the solution that every ml contains 1mg, in contrast product solution.According to the thin layer chromatography test, draw above-mentioned need testing solution 10ul, reference substance solution 5ml, put respectively on same silica gel g thin-layer plate, with petroleum ether (30-60 ℃): ether (3: 2) is developing solvent, launches, and takes out, dry, put under the ultra-violet lamp (365nm) and inspect.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color.
(2) getting this product 5g puts in the round-bottomed flask, add methanol 50ml, reflux 1 hour filters, the methanol solution evaporate to dryness, residue adds water 30ml dissolving, uses water saturation n-butanol extraction 2 times, each 20ml, merge n-butyl alcohol liquid, extract 3 times with ammonia solution, each 20ml discards ammonia solution, n-butyl alcohol liquid is put evaporate to dryness in the water-bath, residue adds water 10ml dissolving, by the D101 macroporous resin column, respectively with water 50ml, 40% ethanol 50ml, 70% ethanol 50ml eluting, collect 70% ethanol elution, evaporate to dryness, residue add methanol 1ml dissolving, as need testing solution.Other gets the astragaloside reference substance, adds methanol and makes the solution that every ml contains 1mg, in contrast product solution.Test according to thin layer chromatography, draw above-mentioned need testing solution 5ml, reference substance solution 2～3ml, put respectively on same silica gel g thin-layer plate, with chloroform: methanol: lower floor's solution of water (13: 7: 2) is developing solvent, launch, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and 100 ℃ to be heated to the speckle colour developing clear.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, the speckle of apparent same color under the daylight; Under the ultra-violet lamp (365nm), show the fluorescence speckle of same color.
(3) get this product 5g, add 10% sodium hydroxide solution 100ml, heating in water bath refluxed 1 hour, put cold, solution is inclined to separatory funnel, use ethyl acetate extraction 2 times, each 50ml merges ethyl acetate liquid, wash with water to neutrality, reclaim ethyl acetate and be concentrated into about 1ml, as need testing solution.Other gets Fructus Xanthii control medicinal material 6g, add 10% sodium hydroxide solution 100ml, heating in water bath refluxed 1 hour, put cold, centrifugal, get supernatant ethyl acetate extraction 2 times, each 50ml merges ethyl acetate liquid, washes with water to neutrality, reclaim ethyl acetate and be concentrated into about 1ml, make control medicinal material solution.According to thin layer chromatography experiment, draw above-mentioned two kinds of each 5ml of solution, put respectively on same silica gel G precoated plate, with toluene: ethyl acetate: glacial acetic acid (16: 4: 1) be developing solvent, launches, and takes out, and dries, and puts in the iodine vapor and smokes 5 minutes.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color.
(4) get this product 5g, add water 30ml dissolving, add ammonia solution 15ml, change in the separatory funnel, add chloroform 50ml extraction, shake well divides and gets chloroform solution, and evaporate to dryness, residue add methanol 1ml dissolving, as need testing solution.Other gets Radix Stemonae control medicinal material 1.5g, adds methanol 10ml ultrasonic 10 minutes, filters, and the filtrate evaporate to dryness adds water 10ml dissolving, add ammonia solution 15ml, change in the separatory funnel, add chloroform 50ml extraction, shake well, divide and get chloroform solution, evaporate to dryness, residue add methanol 1ml dissolving, get control medicinal material solution with legal system.Test according to thin layer chromatography, draw above-mentioned two kinds of each 10ul of solution, put respectively on the silica gel g thin-layer plate that same usefulness 1% sodium hydroxide solution is modulated into, with chloroform: ethyl acetate: methanol: (40: 40: 15: 15) lower floor's solution of placing below 10 ℃ was developing solvent to water, launch, take out, dry, spray is with rare bismuth potassium iodide test solution and 5% sodium nitrite alcoholic solution.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color.
(5) get this product 3g, add ethyl acetate 30ml, supersound process 20 minutes filters, and filtrate evaporate to dryness, residue add methanol 1ml dissolving, as need testing solution.Other gets Fructus Schisandrae Chinensis control medicinal material 1g, shines medical material solution in pairs with legal system.Get the schisandrin reference substance again, add methanol and make the solution that every ml contains 1mg, in contrast product solution.According to the thin layer chromatography test, draw above-mentioned three kinds of each 5ml of solution, put in same silica gel G F respectively
254On the lamellae, with petroleum ether (30-60 ℃): Ethyl formate: the upper solution of formic acid (15: 5: 1) is developing solvent, launches, and takes out, and dries, and puts under the ultra-violet lamp (254nm) and inspects.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescent quenching speckle of same color; With the corresponding position of reference substance chromatograph on, show the fluorescent quenching speckle of same color.
Assay: measure according to high-efficient liquid phase technique.
Chromatographic condition and system suitability test octadecyl silane are filler; Acetonitrile: water (50: 50) is mobile phase; The detection wavelength is 250nm; Column temperature: 23 ℃; Flow velocity: 1.2ml/min.Number of theoretical plate calculates by imperatorin, should be not less than 3000, and separating degree should meet the requirements.
It is an amount of that the imperatorin reference substance is got in the preparation of reference substance solution, and accurate the title decides, and adds methanol and makes the solution that every ml contains 12mg, as need testing solution.
The about 2g of this product is got in the preparation of need testing solution, and accurate the title decides, and puts in the 50ml volumetric flask, add chloroform 30ml, supersound process 30 minutes is put cold, add chloroform to scale, shake up, filter, precision is measured subsequent filtrate 10ml, puts evaporate to dryness in the evaporating dish, and residue adds dissolve with methanol, and move in the 5ml volumetric flask, add methanol and be diluted to scale, methanol solution filters with microporous filter membrane, as need testing solution.
Accurate respectively reference substance solution 10ml, the need testing solution 10ml of drawing of algoscopy injects chromatograph of liquid, measures, promptly.
This product contains the Radix Angelicae Dahuricae with imperatorin (C
16H
14O
4) meter, every must not be less than 0.06mg.
Embodiment 4:
Crude drug: Radix Angelicae Dahuricae 19kg, Flos Magnoliae 12kg, Fructus Xanthii 16kg, Herba Centipedae 12kg, very light blue 16kg, Radix Stemonae 16kg, Radix Astragali 16kg, Fructus Schisandrae Chinensis 5.5kg
Preparation method: 1) Radix Angelicae Dahuricae, the Radix Stemonae, Fructus Schisandrae Chinensis add 6 times of amount alcohol reflux of 75% 3 times, and each 1 hour, filter, merge alcohol extract, reclaim ethanol, being concentrated into relative density is the clear paste of 1.05-1.10 (50 ℃);
2) Flos Magnoliae adds 15 times of amounts of water, and steam distillation 5 hours extracts volatile oil, and the aqueous solution of carrying behind the oil is continued to employ; Volatile oil betacyclodextrin inclusion;
3) add 8 times of amounts of water after Flos Magnoliae medicinal residues and Fructus Xanthii, the Radix Astragali, Herba Centipedae, the very light blue mixing, decoct 3 times, each 1.5 hours, filter filtrate for later use;
4) with 2) in carry aqueous solution and 3 behind the oil) in filtrate merge, being concentrated into relative density is the clear paste of 1.05-1.10 (50 ℃), adds ethanol again and makes and contain the alcohol amount and reach 65%, placement is spent the night, filter, filtrate recycling ethanol, and to continue to be concentrated into relative density be 1.10-1.15 (50 ℃), with 1) middle alcohol extraction clear paste merging, continue to be concentrated into the thick paste that relative density is 1.25-1.30 (50 ℃), drying under reduced pressure is ground into fine powder, again with 2) in inclusion complex mixes, must medicated powder;
5) medicated powder is added dextrin 52kg, microcrystalline Cellulose 5kg, mixing is made pill.
Instructions of taking: three times on the one, each 4～5 grams.
Claims (10)
1. pharmaceutical composition that is used for the treatment of rhinitis is characterized in that this pharmaceutical composition made by following materials of weight proportions medicine:
The Radix Angelicae Dahuricae 190～230 weight portion Flos Magnoliaes 120～160 weight portion Fructus Xanthii 120～160 weight portions
Very light blue 120～160 weight portion Radixs Stemonae of Herba Centipedae 120～160 weight portions 120～160 weight portions
The Radix Astragali 120～160 weight portion Fructus Schisandrae Chinensis 55～85 weight portions.
2. pharmaceutical composition as claimed in claim 1 is characterized in that the optimum ratio of each crude drug is:
The Radix Angelicae Dahuricae 200～220 weight portion Flos Magnoliaes 130～150 weight portion Fructus Xanthii 130～150 weight portions
Very light blue 130～150 weight portion Radixs Stemonae of Herba Centipedae 130～150 weight portions 130～150 weight portions
The Radix Astragali 130～150 weight portion Fructus Schisandrae Chinensis 65～75 weight portions.
3. pharmaceutical composition as claimed in claim 2 is characterized in that the optimal proportion of each crude drug is: the Radix Angelicae Dahuricae 211 weight portions, Flos Magnoliae 141 weight portions, Fructus Xanthii 141 weight portions, Herba Centipedae 141 weight portions, very light blue 141 weight portions, the Radix Stemonae 141 weight portions, the Radix Astragali 141 weight portions, Fructus Schisandrae Chinensis 70 weight portions.
4. as claim 1,2 or 3 described pharmaceutical compositions, it is characterized in that making attainable various dosage forms on the various clinical or medicaments, comprise tablet, capsule, granule, soft capsule, oral liquid etc.
5. preparation of drug combination method as claimed in claim 4 is characterized in that this method comprises following technical process:
1) Radix Angelicae Dahuricae, the Radix Stemonae, Fructus Schisandrae Chinensis add 70%～90% alcohol reflux, and extracting solution reclaims ethanol, and is concentrated into into clear paste;
2) Flos Magnoliae extracts volatile oil with steam distillation, and the aqueous solution of carrying behind the oil is continued to employ; Volatile oil betacyclodextrin inclusion;
3) decoct with water after Flos Magnoliae medicinal residues and Fructus Xanthii, the Radix Astragali, Herba Centipedae, the very light blue mixing, decoction liquor filters, filtrate for later use;
4) with 2) in carry aqueous solution and 3 behind the oil) in filtrate merge, be condensed into clear paste, add ethanol and make and contain alcohol amount and reach 60%～80%, placement is spent the night, filter, filtrate recycling ethanol also concentrates clear paste, with 1) middle alcohol extraction clear paste merging, continue to be condensed into thick paste, drying under reduced pressure, be ground into fine powder, again with 2) in inclusion complex mixes, must medicated powder;
5) the conventional adjuvant of medicated powder and pharmaceutics is mixed mutually, make required dosage form.
6. preparation of drug combination method as claimed in claim 5 is characterized in that the technical process of capsule is as follows:
1) Radix Angelicae Dahuricae, the Radix Stemonae, Fructus Schisandrae Chinensis add 5 times of amount alcohol reflux of 80% 3 times, and each 2 hours, filter, merge alcohol extract, reclaim ethanol, relative density is the clear paste of 1.05-1.10 when being concentrated into 50 ℃;
2) Flos Magnoliae adds 8 times of amounts of water, and steam distillation 6 hours extracts volatile oil, and the aqueous solution of carrying behind the oil is continued to employ; Volatile oil betacyclodextrin inclusion;
3) add 12 times of amounts of water after Flos Magnoliae medicinal residues and Fructus Xanthii, the Radix Astragali, Herba Centipedae, the very light blue mixing, decoct 3 times, each 1 hour, filter filtrate for later use;
4) with 2) in carry aqueous solution and 3 behind the oil) in filtrate merge, relative density is the clear paste of 1.05-1.10 when being concentrated into 50 ℃, adds ethanol and makes and contain alcohol amount and reach 70%, and placement is spent the night, filter, filtrate recycling ethanol and to be concentrated into 50 ℃ of relative densities be 1.10-1.15 is with 1) in the alcohol extraction clear paste merge, relative density is the thick paste of 1.25-1.30 when continuing to be concentrated into 50 ℃, drying under reduced pressure, be ground into fine powder, again with 2) in inclusion complex mixes, must medicated powder;
5) medicated powder is added lactose on a small quantity to regulate medicated powder to suitable degree of adhesion, dry-pressing is granulated, and dresses up capsule.
7. preparation of drug combination method as claimed in claim 6, it is characterized in that wherein the preparation condition of betacyclodextrin inclusion complex is: the weight ratio of volatile oil-betacyclodextrin-water is 1: 8: 60, under 80 ℃ of conditions, stir 1 hour inclusion, cold preservation is spent the night again, sucking filtration, inclusion complex be lower than under 40 ℃ the condition dry, promptly.
8. as the method for quality control of pharmaceutical composition as described in the claim 4, it is characterized in that comprising in this method following one or more qualitative identification methods:
1) get preparation 3～5g of the present invention and put in the tool plug conical flask, the 50ml that adds diethyl ether, supersound process 20 minutes filters, and filtrate is put evaporate to dryness in the water-bath, and residue adds methanol 1ml dissolving, as need testing solution; Other gets imperatorin, isoimperatorin reference substance, adds methanol and makes the solution that every ml contains 1mg, in contrast product solution; According to the thin layer chromatography test, draw above-mentioned need testing solution 10ul, reference substance solution 5ml, put respectively on same silica gel g thin-layer plate, be developing solvent with petroleum ether-ether of 3: 2, launch, take out, dry, put under the 365nm ultra-violet lamp and inspect; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
2) getting preparation 3～5g of the present invention puts in the round-bottomed flask, add methanol 50ml, reflux 1 hour filters, the methanol solution evaporate to dryness, residue adds water 30ml dissolving, uses water saturation n-butanol extraction 2 times, each 20ml, merge n-butyl alcohol liquid, extract 3 times with ammonia solution, each 20ml discards ammonia solution, n-butyl alcohol liquid is put evaporate to dryness in the water-bath, residue adds water 10ml dissolving, by macroporous resin column, respectively with water 50ml, 40% ethanol 50ml, 70% ethanol 50ml eluting, collect 70% ethanol elution, evaporate to dryness, residue add methanol 1ml dissolving, as need testing solution; Other gets the astragaloside reference substance, adds methanol and makes the solution that every ml contains 1mg, in contrast product solution; Test according to thin layer chromatography, draw above-mentioned need testing solution 5ml, reference substance solution 2 ~ 3ml, put respectively on same silica gel g thin-layer plate, lower floor's solution with 13: 7: 2 chloroform-methanol-water is developing solvent, launch, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and 100 ℃ to be heated to the speckle colour developing clear; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, the speckle of apparent same color under the daylight; Under the 365nm ultra-violet lamp, show the fluorescence speckle of same color;
3) get preparation 3～5g of the present invention and add 10% sodium hydroxide solution 100ml, heating in water bath refluxed 1 hour, put cold, solution is inclined to separatory funnel, use ethyl acetate extraction 2 times, each 50ml, merge ethyl acetate liquid, wash with water to neutrality, reclaim ethyl acetate and be concentrated into about 1ml, as need testing solution; Other gets Fructus Xanthii control medicinal material 6g, add 10% sodium hydroxide solution 100ml, heating in water bath refluxed 1 hour, put cold, centrifugal, get supernatant ethyl acetate extraction 2 times, each 50ml merges ethyl acetate liquid, washes with water to neutrality, reclaim ethyl acetate and be concentrated into about 1ml, make control medicinal material solution; According to the thin layer chromatography experiment, draw above-mentioned two kinds of each 5ml of solution, put respectively on same silica gel G plate, be developing solvent with toluene-ethyl acetate-glacial acetic acid of 16: 4: 1, launch, take out, dry, put in the iodine vapor and smoked 5 minutes; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color;
4) get preparation 3～5g of the present invention, add water 30ml dissolving, add ammonia solution 15ml, change in the separatory funnel, add chloroform 50ml extraction, shake well divides and gets chloroform solution, and evaporate to dryness, residue add methanol 1ml dissolving, as need testing solution; Other gets Radix Stemonae control medicinal material 1.5g, adds methanol 10ml ultrasonic 10 minutes, filters, and the filtrate evaporate to dryness adds water 10ml dissolving, add ammonia solution 15ml, change in the separatory funnel, add chloroform 50ml extraction, shake well, divide and get chloroform solution, evaporate to dryness, residue add methanol 1ml dissolving, make control medicinal material solution; Test according to thin layer chromatography, draw above-mentioned two kinds of each 10ul of solution, put respectively on the silica gel g thin-layer plate that same usefulness 1% sodium hydroxide solution is modulated into, with 40: 40: 15: lower floor's solution that chloroform-ethyl acetate of 15-methanol-water is placed below 10 ℃ was developing solvent, launch, take out, dry, spray is with rare bismuth potassium iodide test solution and 5% sodium nitrite alcoholic solution; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color;
5) get preparation 3～5g of the present invention, add ethyl acetate 30ml, supersound process 20 minutes filters, and filtrate evaporate to dryness, residue add methanol 1ml dissolving, as need testing solution; Other gets Fructus Schisandrae Chinensis control medicinal material 1g, shines medical material solution in pairs with legal system; Get the schisandrin reference substance again, add methanol and make the solution that every ml contains 1mg, in contrast product solution; According to thin layer chromatography test, draw above-mentioned three kinds of each 5ml of solution, put respectively on same silica GF254 lamellae, be developing solvent with the upper solution of petroleum ether-Ethyl formates of 15: 5: 1-formic acid, launch, take out, dry, put under the 254nm ultra-violet lamp and inspect; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescent quenching speckle of same color; With the corresponding position of reference substance chromatograph on, show the fluorescent quenching speckle of same color.
9. the method for quality control of pharmaceutical composition as claimed in claim 8 is characterized in that this method also comprises following content assaying method:
Chromatographic condition and system suitability test octadecyl silane are filler; 50: 50 acetonitrile-water is a mobile phase; The detection wavelength is 250nm; 23 ℃ of column temperatures; Flow velocity 1.2ml/min; Number of theoretical plate calculates by imperatorin, should be not less than 3000;
It is an amount of that the imperatorin reference substance is got in the preparation of reference substance solution, and accurate the title decides, and adds methanol and makes the solution that every ml contains 12mg, as need testing solution;
Preparation 2～3g of the present invention is got in the preparation of need testing solution, and accurate the title decides, and puts in the 50ml volumetric flask, add chloroform 30ml, supersound process 30 minutes is put cold, add chloroform to scale, shake up, filter, precision is measured subsequent filtrate 10ml, puts evaporate to dryness in the evaporating dish, and residue adds dissolve with methanol, and move in the 5ml volumetric flask, add methanol and be diluted to scale, methanol solution filters with microporous filter membrane, as need testing solution;
Accurate respectively reference substance solution 10ml, the need testing solution 10ml of drawing of algoscopy injects chromatograph of liquid, measures, promptly.
10. be used for the treatment of application in the medicine of rhinitis as pharmaceutical composition as described in the claim 1,2 or 3 in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510200509A CN1923268B (en) | 2005-09-02 | 2005-09-02 | Medicinal composition for treating rhinitis, its preparing method and quality controlling means |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510200509A CN1923268B (en) | 2005-09-02 | 2005-09-02 | Medicinal composition for treating rhinitis, its preparing method and quality controlling means |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1923268A true CN1923268A (en) | 2007-03-07 |
| CN1923268B CN1923268B (en) | 2010-05-12 |
Family
ID=37816211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200510200509A Expired - Fee Related CN1923268B (en) | 2005-09-02 | 2005-09-02 | Medicinal composition for treating rhinitis, its preparing method and quality controlling means |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1923268B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526546A (en) * | 2012-01-04 | 2012-07-04 | 田胜利 | Chinese medicinal composition and preparation and preparation method thereof |
| CN107875277A (en) * | 2017-11-09 | 2018-04-06 | 苏鑫 | A kind of Chinese medicine for treating nasosinusitis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1038389C (en) * | 1993-02-06 | 1998-05-20 | 费庆祝 | Medicine "Xincangbiyuan powder" for treating rhinitis |
-
2005
- 2005-09-02 CN CN200510200509A patent/CN1923268B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526546A (en) * | 2012-01-04 | 2012-07-04 | 田胜利 | Chinese medicinal composition and preparation and preparation method thereof |
| CN107875277A (en) * | 2017-11-09 | 2018-04-06 | 苏鑫 | A kind of Chinese medicine for treating nasosinusitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1923268B (en) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1895617A (en) | Kidney-warming and heart-nourishing Chinese-medicinal preparation, its making method and quality control | |
| CN1768854A (en) | Chinese medicinal capsule with spleen-supplementing, intestine-benefiting function | |
| CN1785293A (en) | Quality control method of heart pulse free flow oral preparation | |
| CN1824258A (en) | Quality control method of fuyuekang Chinese medicinal preparation | |
| CN1836706A (en) | Chinese traditional medicine composition for treating leucopenia and preparation and quality controlling method thereof | |
| CN1891284A (en) | Chinese medicine composition, and its preparing method and quality control method | |
| CN1733273A (en) | Pulean pharmaceutical preparation, process for preparing the same and quality controlling method thereof | |
| CN1943680A (en) | A Chinese traditional medicinal composition for treatment of endometriosis and its preparation method | |
| CN1923268A (en) | Medicinal composition for treating rhinitis, its preparing method and quality controlling means | |
| CN100341540C (en) | Angelica root mistletoe granules and its preparation method | |
| CN1824245A (en) | Quality control method of bone sinew medicinal pill preparation | |
| CN1785220A (en) | Method for quality control of blood-bonifying Chinese angelica prepn. | |
| CN1689626A (en) | Traditional Chinese medicine compound recipe for treating hyperplasia of mammary glands and preparation method thereof | |
| CN1903265A (en) | Traditional Chinese medicine composition for treating nycturia and its preparing method | |
| CN1785268A (en) | Quality control method of sinew soothing and pain relieving preparation | |
| CN1290557C (en) | Medicine for treating cataract and preparation method thereof | |
| CN1836712A (en) | Pharmaceutical composition for treating sexual disorder and its preparation process | |
| CN1369306A (en) | 'Huajuhong' preparation and its preparing process | |
| CN1827145A (en) | Chinese medicinal composition with beautifying function and method for preparing the same | |
| CN1733287A (en) | Proprietary Chinese traditional medicine with marked effect in treating hysteromyoma, process for preparing the same and quality controlling method thereof | |
| CN100344312C (en) | Prepn process of granule for treating children's hyperkinesia and its quality control method | |
| CN1241586C (en) | Chinese medicine composition and preparing method thereof | |
| CN1261452C (en) | Sugar latticeing material CHB extracted from serum of turtle or/and tortoise, preparation process and application in pharmacy thereof | |
| CN1931272A (en) | Quality control method for gynecopathy treating medicine capsule | |
| CN1742934A (en) | Xianlinggubao granulae preparation, and preparing method and quality control technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GUOLI CHUANGTOU (BEIJING) MEDICAL TECHNOLOGY DEVEL Free format text: FORMER OWNER: HUAXIA YISHENG INNOVATION SCIENCE + TECH. CO., LTD., BEIJING Effective date: 20120720 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120720 Address after: 100027, happy village, No. 55, Beijing, Chaoyang District Patentee after: National venture capital (Beijing) Medical Technology Development Co., Ltd. Address before: 100027, Beijing, Beijing, Chaoyang District Chaoyang District Happy Village No. 55 Patentee before: Beijing Huaxia Yisheng Innovation Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100512 Termination date: 20190902 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |